Onconova Therapeutics, Inc. (ONTX) financial statements (2020 and earlier)
Company profile
| Business Address |
375 PHEASANT RUN NEWTOWN, PA 18940 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 21 | 20 | 44 | 100 | |||||
| Cash and cash equivalents | 21 | 20 | 44 | 60 | |||||
| Short-term investments | 40 | ||||||||
| Restricted cash and investments | 0 | 0 | |||||||
| Receivables | 0 | 0 | 0 | 0 | 2 | ||||
| Prepaid expense | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||
| Other current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed current assets | 23 | 17 | 5 | 1 | 1 | 2 | 3 | ||
| Total current assets: | 23 | 18 | 5 | 23 | 23 | 47 | 104 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Restricted cash and investments | 0 | ||||||||
| Other noncurrent assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||
| TOTAL ASSETS: | 24 | 18 | 5 | 23 | 23 | 47 | 105 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 8 | 6 | 8 | 7 | 4 | 5 | 5 | ||
| Accounts payable | 4 | 4 | 6 | 5 | 3 | 4 | 4 | ||
| Accrued liabilities | 4 | 0 | 0 | 0 | 0 | ||||
| Employee-related liabilities | 2 | 1 | 2 | 0 | 1 | 1 | |||
| Taxes payable | 0 | 0 | |||||||
| Deferred revenue | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | 0 | 0 | 1 | ||
| Contract with customer, liability | ✕ | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other liabilities | 0 | 0 | 0 | 0 | |||||
| Other undisclosed current liabilities | 2 | 2 | 2 | 3 | 5 | 5 | |||
| Total current liabilities: | 8 | 8 | 10 | 10 | 8 | 10 | 10 | ||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 4 | 4 | 4 | 5 | 5 | 13 | 14 | ||
| Deferred revenue and credits | ✕ | ✕ | 4 | 5 | 5 | 13 | 14 | ||
| Deferred revenue | 4 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Contract with customer, liability | ✕ | 4 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other liabilities | 0 | 0 | |||||||
| Other undisclosed noncurrent liabilities | 0 | 0 | 2 | 3 | |||||
| Total noncurrent liabilities: | 4 | 4 | 6 | 8 | 5 | 13 | 14 | ||
| Total liabilities: | 12 | 13 | 16 | 18 | 13 | 24 | 24 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 12 | 5 | (12) | 4 | 10 | 23 | 80 | ||
| Common stock | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 414 | 387 | 351 | 342 | 328 | 317 | 311 | ||
| Accumulated other comprehensive income (loss) | (0) | (0) | 0 | (0) | (0) | (0) | 0 | ||
| Accumulated deficit | (403) | (382) | (362) | (338) | (319) | (295) | (231) | ||
| Stockholders' equity attributable to noncontrolling interest | 1 | 1 | 1 | 1 | 0 | ||||
| Total stockholders' equity: | 12 | 5 | (11) | 5 | 11 | 24 | 81 | ||
| TOTAL LIABILITIES AND EQUITY: | 24 | 18 | 5 | 23 | 23 | 47 | 105 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Gross profit: | 2 | 1 | 1 | 6 | 11 | 1 | 5 | |
| Operating expenses | (24) | (25) | (27) | (29) | (35) | (65) | (67) | |
| Operating loss: | (22) | (23) | (26) | (24) | (24) | (64) | (62) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 0 | 1 | 0 | 0 | (0) | (0) | 0 | |
| Interest and debt expense | (0) | (0) | ||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 0 | 2 | 2 | 4 | 0 | 0 | ||
| Loss from continuing operations before income taxes: | (21) | (21) | (24) | (20) | (24) | (64) | (62) | |
| Income tax expense (benefit) | (0) | 0 | (0) | (0) | (0) | (0) | (0) | |
| Net loss: | (22) | (20) | (24) | (20) | (24) | (64) | (63) | |
| Net income attributable to noncontrolling interest | 0 | 0 | 0 | 0 | ||||
| Other undisclosed net loss attributable to parent | (0) | |||||||
| Net loss attributable to parent: | (22) | (21) | (24) | (20) | (24) | (64) | (63) | |
| Preferred stock dividends and other adjustments | 201 | |||||||
| Other undisclosed net loss available to common stockholders, basic | (204) | |||||||
| Net loss available to common stockholders, diluted: | (22) | (21) | (24) | (20) | (24) | (64) | (65) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (22) | (20) | (24) | (20) | (24) | (64) | (63) | |
| Other comprehensive income (loss) | (0) | (0) | 0 | (0) | (0) | |||
| Other undisclosed comprehensive income | 0 | 0 | ||||||
| Comprehensive loss: | (22) | (20) | (24) | (20) | (24) | (64) | (63) | |
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (0) | 0 | (0) | (0) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (22) | (21) | (24) | (20) | (24) | (64) | (63) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.